Table 4.
Effects on HbA1c, glucose, and lipid parameter variables
| Variable | Efficacy set (n=1,651) | P valuea | |
|---|---|---|---|
|
| |||
| No. (%) | Mean±SD | ||
| HbA1c, % | |||
| Baseline | 1,386 (83.95) | 8.17±1.36 | |
| Follow-up | 1,624 (98.36) | 7.12±1.13 | |
| Changes | 1,368 (82.86) | −1.05±1.35 | <0.0001 |
| Changes, % | 1,368 (82.86) | −11.53±14.04 | <0.0001 |
|
| |||
| Glucose, mg/dL | |||
| Baseline | 1,243 (75.29) | 174.71±58.13 | |
| Follow-up | 1,575 (95.40) | 139.10±44.88 | |
| Changes | 1,211 (73.35) | −34.05±62.00 | <0.0001 |
| Changes, % | 1,211 (73.35) | −14.37±29.89 | <0.0001 |
|
| |||
| Changes by statin administered, mg/dL | |||
| Not administeredb | |||
| Total cholesterol | 380 (23.02) | −12.54±44.05 | <0.0001 |
| Triglyceride | 356 (21.56) | −31.00±110.98 | <0.0001 |
| LDL-C | 324 (19.62) | −9.49±33.00 | <0.0001 |
| HDL-C | 349 (21.14) | 2.06±10.29 | <0.0001 |
| Administeredc | |||
| Total cholesterol | 491 (29.74) | −4.60±32.72 | 0.0257 |
| Triglyceride | 491 (29.74) | −27.10±83.42 | <0.0001 |
| LDL-C | 445 (26.95) | −5.16±28.26 | 0.0008 |
| HDL-C | 487 (29.50) | 4.15±9.79 | <0.0001 |
SD, standard deviation; HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
a
Wilcoxon signed rank sum test,
b
Not administered statin from baseline to last follow-up lab test,
c
Kept administering statin from baseline to last follow-up lab test.